{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45.6"},{"groupId":"OG001","value":"62.3"}]}],"title":"Very satisfied"},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.3"},{"groupId":"OG001","value":"29.5"}]}],"title":"Satisfied"},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.5"},{"groupId":"OG001","value":"4.9"}]}],"title":"Neither satisfied nor dissatisfied"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.8"},{"groupId":"OG001","value":"1.6"}]}],"title":"Dissatisfied"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.8"},{"groupId":"OG001","value":"1.6"}]}],"title":"Missing"}],"denoms":[{"counts":[{"groupId":"OG000","value":"57"},{"groupId":"OG001","value":"61"}],"units":"Participants"}],"description":"The TASQ IV is a 12-item questionnaire that asks questions regarding different aspects of participants' satisfaction with IV administration, experiences related to administration, convenience, and time. The TASQ IV does not have any pre-defined scale or associated numerical scoring and answer choices are qualitative. Question 1 in the TASQ IV evaluates participants' satisfaction or dissatisfaction with IV administration. As pre-specified by the sSAP, the percentage of participants was reported for each response to TASQ-IV Question 1 according to level of satisfaction, for each treatment arm. Treatment arms A (Pembrolizumab Plus Berahyaluronidase alfa SC followed by Pembrolizumab IV) and B (Pembrolizumab IV followed by Pembrolizumab plus Berahyaluronidase alfa SC) were defined as treatment sequence arms in the protocol.","groups":[{"description":"In the Treatment Crossover Period participants first received pembrolizumab plus berahyaluronidase alfa SC for three 21-day cycles, followed by pembrolizumab IV for three 21-day cycles.","id":"OG000","title":"Arm A: Pembrolizumab (+) Berahyaluronidase Alfa SC →Pembrolizumab IV"},{"description":"In the Treatment Crossover Period participants first received pembrolizumab IV for three 21-day cycles, followed by pembrolizumab plus berahyaluronidase alfa SC for three 21-day cycles.","id":"OG001","title":"Arm B: Pembrolizumab IV→Pembrolizumab (+) Berahyaluronidase Alfa SC"}],"paramType":"NUMBER","populationDescription":"The analysis population included all randomized participants who received all three doses of pembrolizumab plus berahyaluronidase alfa SC and all three doses of pembrolizumab IV during the treatment crossover period, and subsequently answered question 1 of the TASQ IV.","reportingStatus":"POSTED","timeFrame":"Up to approximately Day 106","title":"Percentage of Participants That Were Satisfied or Dissatisfied With the IV Method of Administration According to Level of Satisfaction, As Assessed by Therapy Administration Satisfaction Questionnaire -Intravenous (TASQ-IV) Question 1","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}